The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | COSMOS: key updates for MOR208 plus venetoclax for R/R CLL
Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Jennifer Woyach, MD, of the Ohio State University College of Medicine, Columbus, OH, discusses the results of the COSMOS trial (NCT02639910), investigating anti-CD19 MOR208 in combination with venetoclax in chronic lymphocytic leukemia (CLL) patients who discontinued BTK inhibitor therapy. This revealed encouraging activity, with acceptable safety and tolerability.
